Owkin, a French-American startup, which was co-founded in 2016 by Dr. Thomas Clozel a clinical research doctor and former assistant professor in clinical hematology) and Gilles Wainrib, Ph.D.a pioneer in the field of artificial intelligence in biology) has raised $74 million in venture capital. Owkin connects several of the largest medical research centers and pharmaceutical companies in Europe and the U.S. within a federated research ecosystem. Owkin has developed four key components to build this ecosystem: Owkin Loop (the network), Owkin Connect (the technology infrastructure), Owkin Studio (the AI software tool), and Owkin Lab (the expertise).
Owkin Connect is a privacy-preserving, traceable, secure technology that allows the company to connect with research centers in the Owkin Loop network. Using Owkin Connect’s federated learning approach, the data do not move, only algorithms travel. This enables insights from the data to be
collectively shared while guaranteeing privacy for patients and compliance with data ownership.
In October 2019, Owkin published its breakthrough analysis of tumor biology, using an interpretable deep learning model called MesoNet in Nature Medicine. In February 2020, Hepatology published Owkin’s novel deep learning models to predict survival after hepatocellular carcinoma resection from histology slides. Most recently, in May 2020, following a winning entry to the data challenge organized last October by the Société Française de Radiologie et d'imagerie médicale (SFR), Owkin published its methodology
to automatically measure muscular area from CT scans to assess sarcopenia in Diagnostic and Interventional Imaging. In August 2020, Owkin published its novel genomic analysis tool (HE2RNA) in Nature Communications.